Novartis is a global healthcare company based in Switzerland that provides solutions to address the evolving needs of patients worldwide. Our mission is to discover new ways to improve and extend people’s lives. Our vision is to be a trusted leader in changing the practice of medicine.

1. A GLOBAL HEALTHCARE COMPANY
by
PIYUSH TRIPATHI
piyushtripathi1992@rediffmail.com

2. Swiss MN Pharmaceutical Company
Created in 1996 through a merger of Ciba-Geigy &
Sandoz
Headquartered in Basel, Switzerland
Employs nearly 1,19,000 people in 140 countries
Subsidiaries:-

3. Better Patient Outcomes by focusing our Resources
on developing medicines
Science Based Innovation by maintaining substantial
investment in R&D
Lead in Growing Areas of Healthcare by focusing on
patented medicines, generics and eye care.

4. Currency in
Millions of US
Dollars
Dec 31
2011
Dec 31
2012
Dec 31
2013
Dec 31
2014
TOTAL
REVENUES
59,375.0 51,971.0 52,716.0 53,634.0
GROSS PROFIT 40,804.0 36,385.0 36,177.0 36,431.0
OPERATING
EXPENSES
28,040.0 24,000.0 24,706.0 24,511.0
OPERATING
INCOME
12,764.0 12,385.0 11,471.0 11,920.0
NET INTEREST
EXPENSE
-688.0 -673.0 -648.0 -670.0
NET INCOME 9,113.0 9,270.0 9,175.0 10,210.0
*http://www.bloomberg.com/research/stocks/financials/financials.asp

5. 8500
9000
9500
10000
10500
Jan/11
Jan/12
Jan/13
Jan/14

6. Novartis has raised the bar in driving an execution
strategy for industrial data, taking advantage of an
integrated data infrastructure to improve quality,
consistency and productivity across sites while
reducing industrial automation and IT costs.
Novartis is bringing together Information
Technology (IT) and Operational Technology (OT)
within their organization and creating a powerful
manufacturing engine with Operational Intelligence.

7. Expanded Business Model including Pharmaceutical
Unit, Eye Care & Generics, Vaccines etc.
Biotechnology Firm “Chiron” was acquired by
Novartis AG, a Unique & Profitable step.
A Huge Range of Investments.
>200 Projects in Clinical Development including
141 in Pharmaceutical Division, as of July 21, 2015.
Had a Market-cap of around $280 Billion, largest
healthcare company by this metric.

8. Loss of Patents
 Patent protection for a major cancer drug “Glivec”, rejected
in India.
 FDA delays approval of an oral ant-diabetic drug “Galvus”.
Has not Separate Unit for Pediatrics

9. Has a potential to enhance “Sandoz” unit as leading
“state-of-the-art” biosimilars manufacturer.
Can contribute its products & services for
pediatrics.
Novartis said that it won’t invest on R&D in India,
but they should have contribute R&D here because
India is a very favorable country for trials.

10. FDA Warnings : Manufacturing unit in Unterach am
Attersee, Austria.
Criminal investigation of its marketing practices in
Japan for a popular blood pressure medicine
“Diovan”.
Patent expiration & longer term risk of patent
expiry for “Glivec”.

11. https://www.novartis.com
http://www.bloomberg.com
http://www.pharmafile.com/news/179555/novartis
-receives-fda-warning